Novocure (NVCR) Misses Q4 EPS by 15c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. META
6. TSLA
7. SMCI
8. RTX
9. S
10. COF

Go back to Novocure (NVCR) Misses Q4 EPS by 15c

Novocure Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update

February 24, 2022 7:00 AM EST

Full year 2021 net revenues of $535 million, an increase of 8% year-over-year

Invested record $201 million in 2021 in research and development initiatives intended to advance Tumor Treating Fields science and technology

ST. HELIER, Jersey--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today reported financial results for the fourth quarter and full year ended December 31, 2021. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields).

We founded Novocure to exploit the novel observation that... More